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ABSTRACT
Epididymal protease inhibitor (EPPIN) is found on the surface
of spermatozoa and works as a central hub for a sperm surface
protein complex (EPPIN protein complex [EPC]) that inhibits
sperm motility on the binding of semenogelin I (SEMG1) during
ejaculation. Here, we identify EPPIN’s amino acids involved in
the interactions within the EPC and demonstrate that EPPIN’s
sequence C102-P133 contains the major binding site for SEMG1.
Within the same region, the sequence F117-P133 binds the EPC-
associated protein lactotransferrin (LTF). We show that residues
Cys102, Tyr107, and Phe117 in the EPPIN C-terminus are
required for SEMG1 binding. Additionally, residues Tyr107 and
Phe117 are critically involved in the interaction between EPPIN
and LTF. Our findings demonstrate that EPPIN is a key player in
the protein-protein interactions within the EPC. Target identifi-
cation is an important step toward the development of a novel
male contraceptive, and the functionality of EPPIN’s residues
Cys102, Tyr107, and Phe117 offers novel opportunities for
contraceptive compounds that inhibit sperm motility by
targeting this region of the molecule.
contraception, EPPIN, semenogelin I, spermatozoa
INTRODUCTION
The development of a nonhormonal male contraceptive will
provide more contraceptive choices for men and women and
contribute to improving human family health. Although
progress has been slow for a variety of reasons, a number of
promising strategies have appeared in recent years, including
therapeutic ultrasound [1], gamendazol [2, 3], retinoic acid
antagonist BMS-189453 [4], and the sperm proteins GAPDHS
[5], EPPIN [6, 7], and CATSPER [8]. Epididymal protease
inhibitor (EPPIN; official symbol SPINLW1) made its debut as
a target for male contraception in 2004 with the demonstration
that blocking EPPIN’s function in nonhuman primates with
antibodies led to reversible infertility [7]. EPPIN’s function has
since been demonstrated to be both antimicrobial [9, 10] and a
central hub for a sperm surface protein-protein network (EPPIN
protein complex [EPC]) that binds the semen coagulating
protein semenogelin I (SEMG1) as part of the complex [11,
12]. EPPIN-SEMG1 binding plays an essential role in
reproduction by inhibiting ejaculate sperm motility [13–15]
through control of the sperm’s internal pH and calcium levels
[14, 16]. Moreover, the demonstration that antibodies to
EPPIN’s C-terminus could substitute for SEMG1 and that the
epitope-specific contraceptive antibodies from the infertile
nonhuman primates [7] inhibited human sperm motility [14]
made it clear that the SEMG1 binding site on EPPIN was a
human sperm surface drugable target.
As described previously [6], we used the AlphaScreen assay
(Amplified Luminescent Proximity Homogeneous assay) to
develop high-throughput screening (HTS) assays to specifical-
ly ‘‘hit’’ compounds that target EPPIN’s SEMG1 binding site.
These selected compounds target EPPIN with high affinity,
mimic SEMG1 binding, and consequently inhibit human sperm
motility. Therefore, a better understanding of the interaction
between EPPIN and SEMG1 is an important step for the study
of how these compounds bind to EPPIN and for the
development of even more effective sperm motility inhibitors.
In the present study, we determined EPPIN’s amino acid
residues involved in its interaction with SEMG1. Our results
demonstrated that the sequence C102-P133 within EPPIN’s
Kunitz domain contains the major binding residues for
SEMG1. Moreover, the EPC-associated protein lactotransferrin
(LTF) was found to bind the EPPIN sequence F117-P133. The
amino acid residues Cys102, Tyr107, and Phe117 that project
into the central binding pocket for SEMG1 are critical for
EPPIN interaction with SEMG1, whereas residues Tyr107 and
Phe117 are further involved in the binding of LTF. Our results
characterize EPPIN’s residues that could be used as potential
targets for improving the rational design of contraceptive
drugs.
MATERIALS AND METHODS
Production and Expression of Recombinant Proteins
Recombinant EPPIN and SEMG1 constructs were cloned, expressed, and
purified as described in the Supplemental Methods (all Supplemental Data are
available online at www.biolreprod.org). Lyophilized full-length recombinant
human holo lactotransferrin (LTF; Pro-592) purified from transgenic rice was
purchased from Prospec (Ness-Ziona). LTF was resuspended in PBS buffer pH
7.4, aliquoted and stored at 808C until use. The number of different protein
preparations for each recombinant protein used in this study is indicated in
Supplemental Table S1.
In Vitro Site-Directed Mutagenesis
Site-directed mutagenesis of wild-type (wt)-EPPIN at residues Cys86,
Cys102, Cys110, Cys123, Cys127, Tyr107, and Phe117 to alanine residues was
performed using Gene Tailor site-directed mutagenesis system (Invitrogen)
according to the manufacturer’s instructions. EPPIN mutant designations and
mutation sites are shown in Table 1. Mutagenesis products were transformed
into DH5a-T1R Escherichia coli and positive clones selected, followed by
DNA sequencing to confirm the mutation. Recombinant EPPIN mutants were
expressed as described in the Supplemental Methods.
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The AlphaScreen assay is a bead-based technology that allows the study of
different types of biomolecular interactions [for review, see Eglen et al. 17].
When acceptor and donor beads are brought together (200 nm) by the
interacting molecules, the excitation of the donor beads generates singlet-state
oxygen molecules (t1/2 ; 4 lsec), which initiate a chemiluminescent reaction in
the acceptor bead that emits light at 520–620 nm. The AlphaScreen assay was
performed in white opaque 384-well microplates (OptiPlate-384; PerkinElmer)
in a final volume of 20 or 30 ll, depending on the experiment as indicated.
Unless otherwise stated, all dilutions were made in assay buffer (100 mM Tris-
HCl, 0.1% bovine serum albumin, wt/vol, 0.01% casein, wt/vol, 0.01% Tween-
20, vol/vol, pH 8.0). In the AlphaScreen IgG (Protein A) detection kit
(PerkinElmer), acceptor beads were conjugated with Protein A and donor beads
with streptavidin. The experiments were carried out at room temperature and
under subdued lighting.
Each recombinant EPPIN construct (wild-type, truncations, and mutants)
was preincubated with anti-EPPIN Q20E antibody and Protein A acceptor
beads for 30 min. In parallel, recombinant biotinylated (bt)-SEMG1 or bt-LTF
was preincubated with streptavidin donor beads under the same conditions.
Equal volumes of each EPPIN/Q20E/Protein A acceptor beads and bt-SEMG1/
streptavidin donor beads or bt-LTF/streptavidin donor beads were pipetted into
the plate wells. The final concentration of assay components was 58 nM
EPPIN, 1 nM bt-SEMG1 or 4 nM bt-LTF, 2 nM Q20E antibody, and 10 lg/ml
beads. Each set of samples was pipetted in at least four replicates. Plates were
covered with top seal and transferred to a Synergy 2 Multiplatform automated
plate reader (Biotek). After shaking for 2 min, plates were read every 2 h during
16 h: excitation using a 680/30 filter and emission using a 570/100 filter and
data acquired using a modified AlphaScreen protocol in the Gen5 software
(Biotek). A total of nine time points were generated during each experiment.
Negative controls were performed under the same conditions in the absence of
EPPIN, bt-SEMG1, or bt-LTF and in the presence of beads only. A specific
signal for each time point was calculated by subtracting the background signal
(obtained in the absence of bt-SEMG1 or bt-LTF) from its respective total
signal. To monitor assay sensitivity and robustness, signal-to-background (S/B)
ratios and Z0 values were calculated as previously described [18].
Concentration-Response and Competition Experiments
Concentration-response experiments were carried out as described above
using increasing concentrations of wt-EPPIN (1 nM–1 lM) in the presence of
constant concentrations of bt-SEMG1 (0.5–4 nM) or bt-LTF (4–8 nM) in a 20
ll-assay volume. Similarly, increasing concentrations of bt-SEMG1 (0.1 pM–1
nM) or bt-LTF (3 pM–8 nM) were incubated in the presence of a constant
concentration of EPPIN (58 nM). The bead concentration was 10 lg/ml.
Specific counts for each data point were calculated as described above and used
for the determination of EC50 values by nonlinear regression curve fitting.
For competition experiments, wt-EPPIN (10 or 30 nM) and bt-SEMG1 (1
nM) or bt-LTF (2 nM) were incubated in the presence of increasing
concentrations of nonbiotinylated SEMG1 (10 pM–150 nM) or LTF (100
pM–600 nM) in a 30 ll-assay volume. In this case, wt-EPPIN and bt-SEMG1
or bt-LTF were preincubated with their respective beads as described above,
and the solutions were pipetted into the plate wells in the following order: 5 ll
competitor protein dilutions, 10 ll of wt-EPPIN/Q20E/Protein A acceptor
beads, and 15 ll of bt-SEMG1/streptavidin donor beads or bt-LTF/streptavidin
donor beads. The bead concentration was 15 lg/ml. A specific signal for each
competitor concentration point was calculated as described above. The IC50
values were calculated by nonlinear regression curve fitting using the
normalized data as a percentage of the specific binding in the absence of
competitor. AlphaScreen TruHits assay was used as a positive control (for
nonspecific effects) under the same conditions as described in the Supplemental
Methods.
EPPIN Homology Modeling
Three-dimensional homology models for the EPPIN C-terminal region
(K73-P133) were built using the SWISS-MODEL Workspace [19–21]. After
template identification, we chose four templates (Protein Data Bank
identification [PDB ID]) based on the percentage of sequence identity to
EPPIN C-terminus: bovine trypsin inhibitor (aprotinin; 1bpiA), boophilin
(2odyE), textilinin-1 (3bybB), and alpha3 chain of human type VI collagen
(1kthA). EPPIN structural models were then generated using the described
templates as reference structures. We compared the quality of the resulting
three-dimensional models using QMEAN Z-score (global quality of the
generated model) [22]. We selected the model with the highest QMEAN Z-
score and then created EPPIN C-terminal model figures using Swiss-PDB
Viewer 4.04 (Swiss Institute of Bioinformatics) and rendered with POV-Ray
3.6 (Persistence of Vision Raytracer Pty Ltd).
Statistical Analysis
Results were expressed as mean 6 standard deviation (SD) or standard
error of the mean (SEM) from the indicated number of independent
experiments. For statistical significance, one-way analysis of variance
(ANOVA) followed by the Tukey-Kramer test was performed when more
than two groups were compared, whereas the Student t-test was used to
compare two groups; P , 0.05 was considered statistically significant.
Statistical comparisons were performed using Prism 5.0 software.
RESULTS
Characterization of bt-SEMG1 or bt-LTF Binding
to wt-EPPIN
We previously demonstrated that EPPIN coats the surface of
human spermatozoa [12, 15, 23], where it is a central player in
a network of protein-protein interactions with SEMG1 and LTF
as part of the EPC [11, 12]. In the present study, we used the
AlphaScreen assay to determine the EPPIN sequences and
amino acid residues required for binding to SEMG1 and LTF.
We first characterized the binding of recombinant bt-SEMG1
or bt-LTF to recombinant wt-EPPIN in this assay (see
Supplemental Results and Supplemental Fig. S1). The binding
of bt-SEMG1 or bt-LTF to wt-EPPIN was time dependent (Fig.
1A). An increase in the signal was observed during the first 6 h
of incubation, reaching a maximum plateau 8 h after
incubation. The maximum signal was maintained for at least
16 h after incubation (Fig. 1A), demonstrating that the
interaction between wt-EPPIN and bt-SEMG1 or bt-LTF is
highly stable. We performed all further analyses using the
signal measured 16 h after the start of incubation.
Concentration-response experiments performed using in-
creasing concentrations of wt-EPPIN in the presence of three
different concentrations of bt-SEMG1 showed that the binding
of wt-EPPIN to bt-SEMG1 was saturable (Fig. 1B, left panel).
The calculated EC50 (95% confidence interval) was 26.4 (23.3–
29.9), 18.4 (17.2–19.5), and 37.2 (33.7–40.9) when wt-EPPIN
was titrated in the presence of 0.5 nM, 1 nM, and 4 nM bt-
SEMG1, respectively. Moreover, S/B ratios and Z0 values
varied depending on the bt-SEMG1 concentration, achieving
optimal conditions when 58 nM wt-EPPIN and 1 nM bt-
SEMG1 were used (Supplemental Table S2). When increasing
concentrations of bt-SEMG1 were incubated in the presence of
58 nM wt-EPPIN (Fig. 1C, left panel), the calculated EC50 was
0.11 nM (0.1–0.13 nM), and an optimal S/B ratio of 174.6 and
Z0 value of 0.87 were obtained using 1 nM bt-SEMG1.
We observed no saturation when increasing concentrations
of wt-EPPIN were incubated in the presence of 4 and 8 nM bt-
TABLE 1. List of EPPIN mutants used in this study.




mC1–3-EPPIN C127A, C123A, C110A
mC1–4-EPPIN C127A, C123A, C110A, C102A





mFC1–4-EPPIN F117A, C127A, C123A, C110A, C102A
mYC1–4-EPPIN Y107A, C127A, C123A, C110A, C102A










LTF even when the concentration of wt-EPPIN was increased
up to 1 lM (Fig. 1B, right panel). However, the titration of bt-
LTF in the presence of 58 nM wt-EPPIN showed a maximum
plateau within 1–8 nM bt-LTF (Fig. 1C, right panel). Under
these conditions, the calculated EC50 for bt-LTF was 0.43 nM
(0.41–0.48 nM), and an optimal S/B ratio of 29.9 and Z0 value
of 0.81 were obtained using 4 nM bt-LTF. These results
demonstrated the robustness, sensitivity and reliability of the
assay to measure the binding of bt-SEMG1 or bt-LTF to wt-
EPPIN.
Effect of Nonbiotinylated SEMG1 and LTF on the Binding
of bt-SEMG1 or bt-LTF to wt-EPPIN
We investigated the ability of nonbiotinylated SEMG1 and
LTF to displace bt-SEMG1 or bt-LTF from their respective
binding sites on wt-EPPIN. As expected, neither of the
nonbiotinylated proteins had an effect on the signal in the
absence of bt-SEMG1 or bt-LTF (Supplemental Table S3).
SEMG1 competed with bt-SEMG1 for binding wt-EPPIN in a
concentration-dependent manner with a calculated IC50 value
(95% confidence interval) of 5.2 nM (3.9–6.9 nM; Fig. 2A).
Similarly, LTF competed with bt-LTF with an IC50 of 4.8 nM
(3.5–6.5 nM; Fig. 2B).
Interestingly, cross-competition experiments demonstrated
that SEMG1 and LTF inhibited the binding of bt-LTF and bt-
SEMG1, respectively, to wt-EPPIN (Fig. 2, A and B). The
calculated IC50 values were 3.7 nM (3.2–4.4 nM) for LTF-
induced inhibition of wt-EPPIN/bt-SEMG1 binding and 27.8
nM (11.7–65.7 nM) for SEMG1-induced inhibition of wt-
EPPIN/bt-LTF binding. The TruHits assay performed in the
presence of the same concentrations of SEMG1 or LTF
FIG. 1. Characterization of the interaction between wt-EPPIN and bt-SEMG1 or bt-LTF by AlphaScreen assay. A) wt-EPPIN was incubated with bt-SEMG1
(left panel) or bt-LTF (right panel) in a time-course experiment. Background signal was detected when beads were incubated in the absence of wt-EPPIN,
bt-SEMG1, or bt-LTF. Data points represent mean 6 SD of total signal from a representative experiment of four experiments, each performed in four
replicates. B) Concentration-response curve for wt-EPPIN in the presence of constant concentrations of bt-SEMG1 (left panel) or bt-LTF (right panel). C)
Concentration-response curve for bt-SEMG1 (left panel) or bt-LTF (right panel) in the presence of a constant concentration of wt-EPPIN. Specific signal for
each data point was determined by subtracting the background signal from total signal. Data points in B and C represent mean 6 SD of specific signal
from a representative experiment of three experiments, each performed in four replicates. cps¼ counts per second.









confirmed that their inhibitory effect on EPPIN/bt-LTF and
EPPIN/bt-SEMG1 binding, respectively, was specific (Fig. 2,
A and B). These results suggested that SEMG1 and LTF
compete for binding to EPPIN.
Effect of Sequential C-terminal Truncations of EPPIN on Its
Binding to bt-SEMG1 or bt-LTF
Previously, we demonstrated that the C-terminal fragment of
EPPIN containing the Kunitz domain and corresponding to
amino acid residues D75-P133 was responsible for its
interaction with SEMG1 [12]. To determine which region
within the C-terminus of EPPIN is involved in the binding to
SEMG1, we produced three sequential EPPIN C-terminal
truncations lacking residues F117-P133 (EPPIN22–116), C102-
P133 (EPPIN22–101), and C86-P133 (EPPIN22–85; Fig. 3A). We
observed a significant reduction (mean 6 SD; P , 0.01) in the
specific signal by 68.7% 6 5.2 for EPPIN22–116, 77.9% 6 3.8
for EPPIN22–101, and 97.9% 6 3.5 for EPPIN22–85 in
comparison to the specific signal detected with the binding of
wt-EPPIN to bt-SEMG1 (Fig. 3B, left panel).
Next, we tested the binding of each EPPIN C-terminal
truncation to bt-LTF under similar conditions. In this situation,
the total signal observed when EPPIN22–116, EPPIN22–101, and
EPPIN22–85 were incubated with bt-LTF was only slightly
above the background (Supplemental Table S4). When
compared to wt-EPPIN, the specific signal observed with all
the truncations was reduced to less than 1% (Fig. 3B, right
panel). Taken together, these results demonstrated that the
amino acid residues C102-P133 and F117-P133 within the
EPPIN C-terminal region contain the major binding sites for
SEMG1 and LTF, respectively. Furthermore, the results
indicated that these binding sites partially overlap, supporting
the previous result showing that SEMG1 and LTF compete for
wt-EPPIN.
Effect of Point Mutations in EPPIN’s C-Terminal Region
on Its Binding to bt-SEMG1 or bt-LTF
In order to map the EPPIN C-terminal amino acid residues
that are critical for binding to SEMG1 and LTF, we produced
EPPIN mutants by site-directed mutagenesis (Table 1).
Considering the previous observation that Cys239 in the
SEMG1 sequence was necessary for interaction with EPPIN
[12], we first evaluated the effect of sequential mutations on
EPPIN cysteine residues 86, 102, 110, 123, and 127. We
observed that single mutations C127A (mC1-EPPIN) and
C123A (mC2-EPPIN), as well as double C127A:C123A
(mC1,2-EPPIN) and triple C127A:C123A:C110A (mC1–3-
EPPIN) mutations, had no effect on EPPIN binding to bt-
SEMG1 when compared to the wild type (Fig. 4A). However,
we detected a significant reduction in the signal by 51.3% 6
6.1 (mean 6 SD; P , 0.01) when the EPPIN mutant
containing quadruple mutation C127A:C123A:C110A:C102A
(mC1–4-EPPIN) was compared to wt-EPPIN (Fig. 4A). To
investigate whether EPPIN’s Cys102 residue alone could
disrupt the binding of bt-SEMG1, we produced an EPPIN
mutant containing a single mutation C102A (mC4-EPPIN). Our
results demonstrated a significant reduction in the signal by
42.2% 6 3.0 when mC4-EPPIN was compared to the wild type
(Fig. 4A), indicating that the residue Cys102 of EPPIN is
involved in the binding of SEMG1. Furthermore, we observed
no additional reduction in the signal when the EPPIN mutant
containing an additional mutation on residue Cys86 to alanine
(quintuple mutant, mC1–5-EPPIN) was compared to mC1–4-
EPPIN and mC4-EPPIN (Fig. 4A).
To further characterize the EPPIN amino acids involved in
binding to SEMG1, we developed a homology model of
EPPIN’s C-terminus (residues K73-P133; Fig. 5). We selected
the serine protease inhibitor aprotinin (bovine trypsin inhibitor;
PDB ID 1bpiA [24]) as the reference structure because it
provided a model with the highest QMEAN Z-score (0.68)
among the reference protein structures tested (Supplemental
Table S5). The EPPIN C-terminus three-dimensional model
contains the three-disulfide bridges and secondary-structure
arrays typical of the Kunitz domain [25] (Fig. 5B). In this
model, we observed that the aromatic side chains of residues
Tyr107 and Phe117 were located at the N- and C-terminus,
respectively, of a loop that is part of the epitope of
contraceptive antibodies from infertile nonhuman primates
[7] and the binding sequence for SEMG1 (Fig. 5C). Therefore,
we performed mutations on these residues: Tyr107 and/or
Phe117 to alanine (Table 1). We observed that Y107A (mY-
EPPIN) and F117A (mF-EPPIN) mutations significantly
reduced the binding to bt-SEMG1 by 68.4% 6 3.8 and
68.7% 6 3.8 (P , 0.01), respectively, in comparison to wt-
EPPIN (Fig. 4B). The specific signal was reduced to a similar
level when the double mutation Y107A:F117A (mYF-EPPIN)
was tested (65.8% 6 4.3; Fig. 4B). Similarly, we observed a
significant reduction in the specific signal by 66.4% 6 4.7,
66.8% 6 5.0, and 69.0% 6 3.8 when mutations Y107A
(mYC 1 – 4 -EPPIN) , F117A (mFC 1 – 4 -EPPIN) , and
FIG. 2. Displacement of bt-SEMG1 (A) or bt-LTF (B) from their respective binding sites on wt-EPPIN by nonbiotinylated SEMG1 or LTF; wt-EPPIN was
incubated with bt-SEMG1 or bt-LTF in the presence of increasing concentrations of SEMG1 or LTF. Specific signal for each data point was determined by
subtracting the background signal from total signal and then normalized as percentage of specific signal in the absence of SEMG1 or LTF. Control
experiments were performed with AlphaScreen TruHits in the presence of SEMG1 of LTF under similar conditions. Data are expressed as mean 6 SD from










Y107A:F117A (mYFC1–4-EPPIN), respectively, were associ-
ated with quadruple Cys-mutation C127A:C123A:C110A:-
C102A (Fig. 4B). Therefore, the reduction in the signal caused
by mutations Y107A and/or F117A on EPPIN sequence was
not affected by mutations on the indicated cysteine residues.
Consequently, we conclude that residues Cys102, Tyr107, and
Phe117 in the C-terminal region of EPPIN play a major role in
the binding of SEMG1.
In parallel, we investigated the binding of EPPIN mutants to
bt-LTF. In this case, we tested only mutants mC1-EPPIN
(C127A), mC2-EPPIN (C123A), mF-EPPIN (F117A), and
mC1,2-EPPIN (C127A:C123A) because they contain mutations
in residues that are part of the F117-P133 fragment, which was
shown to be critical for EPPIN interaction with LTF (Fig. 3B,
right panel). We observed no difference in the signal when
EPPIN mutants mC1-EPPIN, mC2-EPPIN, and mC1,2-EPPIN
were compared to wt-EPPIN (Fig. 4C). However, we detected
a significant reduction of 73.7% 6 3.6 (P¼0.002) in the signal
when mF-EPPIN was compared with wt-EPPIN (Fig. 4D).
These results indicated that EPPIN’s residues Tyr107 and
Phe117 are critical for the binding of LTF.
DISCUSSION
In the present study, amino acids C102-P133 and F117-
P133 of the EPPIN C-terminus were identified as containing
the major binding sites for SEMG1 and LTF, respectively.
Within these sequences, residues Cys102, Tyr107 and Phe117
play key roles in these interactions. Therefore, our results
suggest that EPPIN’s residues Cys102, Tyr107, and Phe117
should be explored as targets for contraceptive drug design.
We developed and validated a nonradioactive quantitative
bioassay for evaluating EPPIN interactions with SEMG1 and
LTF using the AlphaScreen technology. As indicated by Z0
values greater than 0.7, high S/B ratios, and low variability, the
developed assay was robust and sensitive, making it suitable
for HTS purposes [26, 27]. In fact, we have successfully used
this assay in a series of HTS studies to identify lead compounds
that block SEMG1 binding to EPPIN [6].
Titration curves demonstrated that the binding of bt-SEMG1
and bt-LTF to wt-EPPIN was concentration dependent and
saturable. Interestingly, a plateau was not reached when wt-
EPPIN was titrated in the presence of bt-LTF, which may
indicate the capacity of LTF to bind multiple EPPIN molecules.
The time-dependent pattern of the binding of bt-SEMG1 and
bt-LTF to EPPIN (Fig. 1A) suggests that in our assay
conditions these interactions have a slow kinetics but were
highly stable. We noted that the order of addition of the assay
components did not affect the observed time-course pattern.
We do not have an explanation for this observation; however,
the interaction between these proteins may have a slow
association rate and a high on/off ratio. Support for this
hypothesis is provided by studies demonstrating a time-
dependent effect of SEMG1 on binding to spermatozoa and
reducing their forward motility [13, 14]. However, we cannot
rule out the possibility that it may take longer for EPPIN and/or
FIG. 3. Effect of sequential C-terminal truncations of EPPIN on bt-SEMG1 or bt-LTF binding. A) Schematic representation of recombinant EPPIN
fragments P22-P133 (wt-EPPIN; full length lacking the signal peptide) and sequential C-terminal truncations P22-N116, P22-T101, and P22-P85. WAP (N-
terminal) and Kunitz (C-terminal) domains are indicated by dashed and solid lines, respectively. B) EPPIN constructs were incubated with bt-SEMG1 (left
panel) or bt-LTF (right panel). Specific signal for each EPPIN construct was determined by subtracting the background signal from total signal and then
normalized as percentage of specific signal for wt-EPPIN. Data are expressed as mean 6 SEM from the indicated number of experiments, each performed
in six replicates. Different letters in the same bar graphic mean statistically significant differences (ANOVA, followed by Tukey test; P , 0.01).









its binding partners to achieve the proper folding that is
required for their interaction in the assay conditions.
As expected, competition experiments demonstrated that
nonbiotinylated SEMG1 and LTF effectively inhibited the
interaction between their biotinylated counterparts to wt-
EPPIN with calculated IC50 in the low nanomolar range,
confirming the specificity of the assay. LTF and SEMG1
specifically inhibited the binding of wt-EPPIN to bt-SEMG1
and bt-LTF, respectively, indicating that there are amino acids
in the EPPIN Kunitz domain simultaneously involved in both
interactions. Indeed, binding studies using C-terminal truncated
EPPIN (Fig. 3) suggested that the major binding sites for
SEMG1 and LTF on EPPIN partially overlap. SEMG1 binds to
EPPIN’s C-terminal sequence C102-P133, while LTF binds to
F117-P133. These results confirmed the previous observation
that the EPPIN Kunitz domain is critical for its interaction with
SEMG1 [12, 14] and further demonstrated that it contains a
binding site for LTF. Modulatory sites involved in the
inhibition of proteases PSA (Leu87 [28]) and elastase [9] were
identified within EPPIN’s Kunitz domain, suggesting its
critical role in the multifunctional properties of EPPIN.
Our results demonstrated that sequential point mutations in
consecutive cysteine residues 127, 123, and 110 to alanine did
not affect the binding of SEMG1 or LTF to EPPIN. Although
these cysteine residues could be important to stabilize the three-
dimensional structure of EPPIN’s Kunitz domain, they are
unlikely to be involved in the interactions within the EPC. On
the other hand, the single point mutation of Cys102 to alanine
reduced EPPIN binding to SEMG1 by approximately 45% of
the wild type, suggesting that it plays a critical role in EPPIN-
SEMG1 interaction. Since previous studies demonstrated that
reduction and carboxymethylation of SEMG1’s unique cyste-
ine residue (Cys239) blocks the binding of EPPIN [12], it is
possible that a disulfide link occurs between SEMG1’s Cys239
and EPPIN’s Cys102 residue. The fact that EPPIN containing
C102A mutation was still able to bind SEMG1 indicated that
other types of interactions must be involved in EPPIN-SEMG1
binding. Additional studies will be required to confirm this
hypothesis, including the identification of other amino acid
residues, in addition to Cys239, in SEMG1 that are involved in
its interaction with EPPIN.
To visualize the EPPIN binding site for SEMG1 and LTF,
we used the SWISS-MODEL Workspace [19–21] to build a
three-dimensional model of the EPPIN C-terminus (Fig. 5)
because a crystal structural is not available for EPPIN. The
bovine trypsin inhibitor [24] was chosen as the reference
structure because it has greater than 40% sequence identity
with EPPIN’s C-terminus and provided a model with the best
global quality estimation among the generated models. The
QMEAN Z-score of 0.68 for this model indicated that the
structure was within the good-quality range for theoretical
protein structure models [22]. The EPPIN C-terminal model
FIG. 4. Effect of point mutations on EPPIN on bt-SEMG1 (A and B) or bt-LTF (C and D) binding. EPPIN mutant designations and mutation sites are shown
in Table 1. EPPIN constructs were incubated with bt-SEMG1 or bt-LTF. Specific signal for each EPPIN construct was determined by subtracting the
background signal from total signal and then normalized as percentage of specific signal for wt-EPPIN. Data are expressed as mean 6 SEM from the
indicated number of experiments, each performed in six replicates. Different letters in the same bar graphic mean statistically significant differences










allowed us to visualize the typical distribution of the three
disulfide bonds present in the Kunitz domain [25] (Fig. 5, A
and B). Within this three-dimensional model, we noted the
presence of two large hydrophobic residues (Tyr107 and
Phe117), each one located in the N-terminus and C-terminus,
respectively, of a loop that contains a repeat of asparagine
residues (N113-N116) (Fig. 5, A and C). It is worth noting that
residues Tyr107 and Phe117 are highly conserved among
proteins containing the Kunitz-type protease inhibitor motif,
including those with high levels of expression in the male
reproductive tract, such as EPPIN [23, 29], WFDC6, WFDC8,
[30] and the recently described SPINT3, SPINT4, and SPINT5
[31]. Our results demonstrated that single point mutations in
either of these amino acids reduced EPPIN binding to SEMG1
or LTF by approximately 70% when compared to the wild
type, leading to the conclusion that they are critically involved
in the macromolecular interactions within the EPC.
Residues Tyr107 and Phe117 are part of the epitope
recognized by the contraceptive antibodies of the infertile
male monkeys [7] and the epitope-specific anti-EPPIN
antibody S21C (SMFVYGGCQGNNNNFQSANC), both of
which cause a dramatic inhibitory effect on human sperm
motility by mimicking the effects of SEMG1 after it binds to
EPPIN [6, 14, 16]. Conserved protein sequences containing
aromatic side chain amino acid residues, such as phenylalanine,
are usually recognized as protein binding hot spots and are
likely to be protein-protein interaction surfaces and conse-
quently potential targets for rational drug design [32].
Therefore, our results demonstrate that new sperm motility
inhibitors that selectively bind EPPIN’s residues Cys102,
Tyr107, and Phe117 could be developed as potential male
contraceptive drugs.
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